Fig. 4.
Weekly anti-PD-L1 intraperitoneal injections started early increase survival in WT mice with high levels of naturally occurring anti-tumor antibodies. a ELISA measurement of anti-MUC1 IgG antibodies in sera from non-MUC1 transgenic littermates (WT mice) challenged IP with 8 × 105 2F8 cells. The optical density (OD) at 450 nm is shown on the y axis. b Kaplan–Meier survival curve of survival in wild-type mice treated biweekly with isotype control (n = 5, dotted line) or anti-PD-L1 antibody (n = 5, solid line). c Modified protocol schema for dose-intense weekly treatment, starting at day 11 post-tumor challenge. Mice received weekly anti-PD-L1 alone or in combination with IFNα (10,000 IU). d Kaplan–Meier curve of survival for WT mice treated with IgG (n = 5, red intermittent line), anti-PD-L1 (black circles) or anti-PD-L1/IFNα (n = 4, blue solid line). e Heat map analysis of 59 DE genes by Nanostring (q < 0.15) of which 20 were upregulated and 39 were downregulated in anti-PD-L1/IFNα treated (n = 4) versus control animals (n = 4). f Top seven canonical pathways identified through IPA, using the 59 genes in e. g Percentages of splenic CD3+ T cells by flow cytometry. **p < 0.001, ANOVA